Title: The relationships between depression, inflammation and self-reported disease activity in
IBD and their impact on healthcare usage.
Version: 2 Date: 20 Nov 2024
Reviewer:  A. Barney Hawthorne
Reviewer's report:
This is a useful, well-written study, with adequate sample size and good methodology.
1) The main limitations are covered in the Discussion, but it would be helpful to spell out clearly,
what I consider to be the major limitation: which is that patients recruited to boost had to be
symptomatic individuals in clinical remission. This has selected a group more likely to have
functional symptoms.
2) the subset with calpro >200 (presumably about 120 pts could be assessed as a subgroup to
see if the associations/lack of associations remained
3)does the use of significant fatigue as an additional factor in the analysis make any difference?
Title: The relationships between depression, inflammation and self-reported disease activity in
IBD and their impact on healthcare usage.
Version: 2 Date: 20 Nov 2024
Reviewer:  A. Barney Hawthorne
Reviewer's report:
This is a useful, well-written study, with adequate sample size and good methodology.
1) The main limitations are covered in the Discussion, but it would be helpful to spell out clearly,
what I consider to be the major limitation: which is that patients recruited to boost had to be
symptomatic individuals in clinical remission. This has selected a group more likely to have
functional symptoms.
2) the subset with calpro >200 (presumably about 120 pts could be assessed as a subgroup to
see if the associations/lack of associations remained
3)does the use of significant fatigue as an additional factor in the analysis make any difference?
Please review this paper.
user
Title: The relationships between depression, inflammation and self-reported disease activity in
IBD and their impact on healthcare usage.
Version: 2 Date: 20 Nov 2024
Reviewer:  A. Barney Hawthorne
Reviewer's report:
This is a useful, well-written study, with adequate sample size and good methodology.
1) The main limitations are covered in the Discussion, but it would be helpful to spell out clearly,
what I consider to be the major limitation: which is that patients recruited to boost had to be
symptomatic individuals in clinical remission. This has selected a group more likely to have
functional symptoms.
2) the subset with calpro >200 (presumably about 120 pts could be assessed as a subgroup to
see if the associations/lack of associations remained
3)does the use of significant fatigue as an additional factor in the analysis make any difference?
assistant